High-Dose Chemotherapy in the Treatment of Relapsed Osteosarcoma: An Italian Sarcoma Group Study

By F. Fagioli, M. Aglietta, A. Tienghi, S. Ferrari, A. Brach del Prever, E. Vassallo, A. Palmero, E. Biasin, G. Bacci, P. Picci, and E. Madon

Purpose: **To study the feasibility and activity of two courses of high-dose chemotherapy (HDCT) in patients with osteosarcoma in metastatic relapse.**

Patients and Methods: **Patients with high-grade osteosarcoma in metastatic relapse (multiple metastases or solitary metastasis at intervals of less than 30 months) were eligible for study. High-dose chemotherapy consisted of carboplatin and etoposide followed by stem-cell rescue. A second course was planned 4 to 6 weeks after the first. Surgery was performed before or after HDCT.**

Results: **Thirty-two patients were enrolled onto the study. At the end of the treatment, 25 patients were in complete remission (CR), six were alive with disease progression, and one died of toxicity. At present, 14 patients are alive with a median survival time of 23 months from study entry: four are in first CR, three are in second CR, and one is in fourth CR. Six patients are alive with disease. Eighteen patients (56%) died: 17 of disease and one of toxicity. Transplantation-related mortality was 3.1%. The relapse or progression disease rate was 84.4%. The 3-year overall survival rate is 20% and the 3-year disease-free survival rate is 12%.**

Conclusion: **HDCT combined with surgery is feasible and can induce CR in a large portion of patients. Two points, however, need to be considered: only patients who are chemosensitive to induction treatment can obtain CR after HDCT, and the length of remission is short, because most patients relapse. Thus novel strategies are needed to maintain the remission status or to treat patients who do not respond to induction treatment.**

J Clin Oncol 20:2150-2156.

THE PROGNOSIS OF patients with high-grade osteosarcoma has greatly improved over the past 25 years, with overall survival rates increasing from 15% to 70%. This improvement is attributed to (1) the effect of preoperative chemotherapy,[1-4] (2) the introduction of aggressive chemotherapy with various combinations of high-dose methotrexate, doxorubicin, cisplatinum, and ifosfamide,[5-8] (3) the identification of the relationship of dose-response between methotrexate, doxorubicin, cisplatinum, and osteosarcoma cells,[9,10] and (4) the recognition of the main prognostic factor, such as the histologic response to preoperative chemotherapy, which might change postoperative chemotherapy.[11,12]

The prognosis of patients with osteosarcoma in metastatic relapse is very poor, with overall survival rates between 0% and 50% after metastasectomy and aggressive second-line chemotherapy.[13-17] In an attempt to improve survival for patients in metastatic relapse, the Italian and Scandinavian Sarcoma Group devised a prospective phase II protocol with high-dose chemotherapy (HDCT) and peripheral-blood stem-cell (PBSC) reinfusion.[18,19] This approach seems attractive for the pharmacokinetic data available in osteosarcoma patients,[20,21] but the nonhematopoietic toxicity of methotrexate, doxorubicin, cisplatinum, and ifosfamide[9,22-24] makes these agents unsuitable for dose escalation in HDCT. For HDCT, we chose carboplatin and etoposide because of their suitable toxicity profile. Recent data indicate considerable activity of etoposide against bone and soft tissue sarcomas when it is administered in a long-term infusion, taking advantage of the phase specificity of this agent.[25,26] Carboplatin has also been shown to have antitumor activity in osteosarcoma.[27-31]

PATIENTS AND METHODS

Selection of Patients

Patients with high-grade osteosarcoma in metastatic relapse were considered eligible for this protocol if they had multiple metastases or solitary metastasis at intervals of less than 30 months from diagnosis, were younger than 40 years of age, and had normal hepatic and renal function, a WBC count greater than 3.0×10^9/L, and platelets greater than 100×10^9/L. Before entering this protocol, patients underwent a physical examination, a chest computed tomography, and a radionuclide bone scan. Careful enumeration and measurement of all metastatic sites was required. All patients or their legal guardians signed a

From the Department of Pediatrics, University of Turin; Department of Clinical Oncology, Ordine Mauriziano–Institute for Cancer Research and Treatment, Turin; Department of Oncology, Ospedale S. Maria delle Croci, Ravenna; and Department of Chemotherapy, Department of Musculoskeletal Tumors, Istituto Ortopedico Rizzoli, Bologna, Italy.

Submitted June 15, 2001; accepted January 21, 2002.

Supported in part by the Italian Association for Cancer Research, Milan, Italy (E.M. and M.A).

Address reprint requests to Franca Fagioli, MD, Department of Pediatrics, University of Turin, Piazza Polonia 94, 10126 Turin, Italy; email: fagioli@pediatria.unito.it.

0732-183X/02/2008-2150/$20.00

10.1200/JCO.2002.08.081

document of informed consent consistent with local institutional review board guidelines.

Treatment

Mobilization of PBSCs was performed using cyclophosphamide 4 g/m^2 (day 1) and etoposide 100 mg/m^2 over 1 hour every 12 hours (days 2, 3, and 4; total dose, 600 mg/m^2). Granulocyte colony-stimulating factor 10 μg/kg/d was started 48 hours after chemotherapy. The CD34$^+$ cell number required for two re-infusions was 5×10^6/kg.

High-dose chemotherapy consisted of a 2-hour infusion of carboplatin 375 mg/m^2/d for 4 days and continuous-infusion etoposide 450 mg/m^2/d for 4 days. PBSCs were infused 48 hours after the end of HDCT. The first cycle of HDCT was planned 1 to 2 weeks after mobilization and the second cycle, 4 to 6 weeks after the first. The protocol outline is shown in Fig 1.

Granulocyte colony-stimulating factor 5 μg/kg/d was administered from day +1 until the neutrophil count was more than 1×10^9/L for 3 consecutive days. Patients were nursed in a single room at positive air pressure and received oral nonabsorbable antibiotics (gentamicin and nystatin). *Pneumocystis carinii* prophylaxis was performed with nebulized pentamidine 300 mg every 3 weeks from the first day of HDCT.



Fig 1. Protocol outline. CE, cyclophosphamide 4,000 mg/m^2 (day 1); etoposide 200 mg/m^2/d (days 2, 3, and 4). HDCT: etoposide 1,800 mg/m^2 (4 days continuous intravenous infusion), carboplatin 1,500 mg/m^2 (4 days). PBSC rescue at 48 hours after termination of chemotherapy. When possible, surgery was performed within 3 weeks before CE or 4 to 6 weeks after the second transplantation.

The surgical management of the metastatic sites was left to the discretion of the individual surgeon. However, surgical removal of all metastatic sites was strongly encouraged.

Toxicity

Extra-hematopoietic toxicity was graded according to the Bearman score.[32]

Table 1. Patient Characteristics at Study Entry

Patient No.	Sex	Site at Diagnosis	First-Line Therapy	Age at Study Entry (years)	No. of Relapses	Months From Diagnosis	Site of Relapse (last)	No. of Lung Metastases	Mono- or Bilateral Lung Metastases
1	F	Tibia	NEO*5*	14	I	24	Lung	13	Bilateral
2	M	Fibula	Pilot ISG-SSG I	13	I	22	Lung	2	Monolateral
3	F	Fibula	Pilot ISG-SSG I	14	I	17	Lung	1 (13 cm)	Monolateral
4	M	Humerus	Pilot ISG-SSG I	12	I	15	Lung	13	Bilateral
5	M	Femour	Pilot ISG-SSG I	13	I	21	Lung	2	Monolateral
6	F	Femour	Pilot ISG-SSG I	8	I	22	Lung	2	Monolateral
7	M	Femour	ISG-SSG I	13	I	12	Lung	5	Bilateral
8	M	Tibia	ISG-SSG I	13	I	15	Bone + lung	2	Monolateral
9	M	Humerus	ISG-SSG I	9	I	18	Lung	2	Monolateral
10	M	Tibia + fibula	NEO*5*	23	I	52	Lung	4	Monolateral
11	M	Tibia	ISG-SSG I	12	I	10	Lung	2	Bilateral
12	F	Tibia	Pilot ISG-SSG I	20	I	23	Lung	2	Bilateral
13	M	Femour	Pilot ISG-SSG I	16	I	19	Lung	4	Bilateral
14	M	Tibia	ISG-SSG I	22	I	18	Lung	5	Bilateral
15	M	Femour	ISG-SSG I	36	I	18	Lung	7	Bilateral
16	M	Femour	ISG-SSG I	17	I	16	Lung	5	Bilateral
17	M	Fibula	NEO4	25	I	41	Lung	3	Monolateral
18	M	Tibia	Pilot ISG-SSG I	26	I	34	Lung	2	Bilateral
19	F	First cervical vertebra	NEO*5*	38	I	45	Lung	2	Monolateral
20	M	Tibia	Pilot ISG-SSG I	21	I	27	Bone + lung	20	Bilateral
21	F	Femour	ISG-SSG I	21	I	12	Lung + lymph node	1	Monolateral
22	F	Femour	NEO*5*	13	II	31	Lung	4	Bilateral
23	F	Fibula	NEO*5*	15	II	26	Bone + lung	1	Monolateral
24	F	Fibula	Pilot ISG-SSG I	16	II	23	Lung	7	Bilateral
25	F	Radius	NEO4	14	II	35	Bone		
26	M	Femour	ISG-SSG I	15	II	15	Lung	7	Bilateral
27	F	Fibula	Pilot ISG-SSG I	12	II	31	Lung	3	Bilateral
28	F	Humerus	NEO*5*	7	II	49	Lung + lymph node	1 (15 cm)	Monolateral
29	F	Humerus	ISG-SSG I	23	II	21	Lung	2	Bilateral
30	M	Tibia	NEO*5*	17	III	39	Lung	3	Monolateral
31	M	Femour	ISG-SSG I	18	III	32	Lung	1 (paracardiac)	Monolateral
32	M	Tibia	ISG-SSG I	17	III	29	Lung	3	Bilateral

Abbreviations: F, female; M, male; ISG-S G, Italian and Scandinavian Sarcoma Group.

Table 2. Characteristics of Previous Relapses in Patients With More Than One Relapse Before Study Entry

Patient No.	Time From Diagnosis to First Relapse (months)	Site of First Relapse	Therapy for First Relapse	Time From First to Second Relapse (months)	Site of Second Relapse	Therapy for Second Relapse	Time From Second to Third Relapse (months)
22	26	Lung	Surgery	5	Lung		
23	19	Bone	Surgery	7	Bone + lung		
24	20	Lung	Surgery	2,5	Lung		
25	35	Lung	Surgery	42	Bone		
26	9	Lung	Surgery	6	Lung		
27	18	Lung	Surgery	13	Lung		
28	45	Lymph node	Surgery	4	Lung + lymph node		
29	14	Lung	Surgery	7	Lung		
30	30	Bone	Surgery	4	Lung	Surgery	5
31	24	Lung	Surgery	4,5	Lung	Surgery	3
32	20	Lung	Surgery	6	Lung	Surgery	3

Clinical Response

Response of lung metastases was assessed radiologically by computed tomography scan. Isotope bone scans were also performed to monitor bone metastases.

Definitions of response were as follows: complete remission (CR), radiologic disappearance of all evidence of metastasis; partial response (PR), ≥ 50% reduction in the tumor diameters at all sites; stable disease (SD), less than 50% decrease or less than 25% increase in the size of one or more lesions; and progressive disease (PD), more than 25% increase in the size of one or more of the metastases.

Statistical Analysis

Survival analysis was carried out using the Kaplan-Meier method.[33] Event-free survival was defined as the time from the day of transplantation until disease progression or any other cause of death.

Table 3. Outcome of Treatment With Primary and Secondary Surgery, Mobilizing Cycle, and HDCT in All Patients

Patient No.	Outcome After Primary Surgery	Disease Status After Mobilizing Cycle	Disease Status After HDCT	Status at the End of Treatment With Secondary Surgery	Months From End of Treatment to Relapse	Follow-Up and Months From Study Entry
1	CR	CR	CR	CR	3	Dead, 15
2	CR	CR	CR	CR	9,5	Dead, 28
3	CR	CR	CR	CR	6	Dead, 10
4	CR	CR	CR	CR	13	Dead, 29
5	CR	CR	CR	CR		Alive 1st CR, 36+
6	CR	CR	CR	CR	8	Dead, 14
7	PR	PR	PD	PD		Dead, 11
8	NA	SD	PD	PD		Dead, 12
9	NA	SD	SD	CR		Alive 1st CR, 22+
10	CR	CR	CR	CR		Alive 1st CR, 20+
11	NA	SD	SD	CR		Alive 1st CR, 7+
12	NA	SD	PD	PD		Dead, 11
13	NA	SD	SD	CR	5	Alive PD, 26+
14	NA	SD	SD	CR	10	Alive 2nd CR, 24+
15	NA	SD	SD	CR	4	Dead, 16
16	CR	CR	CR	CR	7	Dead, 18
17	NA	PR	PR	CR	13	Alive PD, 19+
18	NA	SD	SD	CR	9,5	Dead, 25
19	CR	CR	CR	CR	8	Dead, 21
20	NA	SD	PD	PD		Alive PD, 13+
21	PR	PR	PR	CR	3	Dead, 8
22	NA	PR	PR	PD		Dead, 13
23	NA	SD	PD	PD		Dead, 29
24	NA	PR	CR	CR	13	Dead, 33
25	CR	CR	CR	CR	15	Alive 4th CR, 30+
26	PR	PR	CR	CR	6	Alive PD, 25+
27	NA	SD	SD	CR	13	Alive 2nd CR, 20+
28	CR	CR	CR	CR	5	Alive PD, 17+
29	NA	SD	Dead	Dead		Dead, 3
30	NA	PR	CR	CR	12	Dead, 39
31	NA	PR	CR	CR	4	Alive PD, 11+
32	NA	SD	SD	CR	2	Alive 2nd CR, 8+

Abbreviation: NA, not assessable.

RESULTS

Thirty-two Italian patients (19 male and 13 female) were enrolled onto this study. At the time of study, median patient age was 15 years (range, 8 to 38 years). The site of relapse was mainly the lung. Twenty-one patients were in first relapse at a median of 20 months (range, 10 to 52 months) from diagnosis. All except one had two or more mono- or bilateral metastases. Eight patients were in second relapse at a median of 28.5 months (range, 15 to 77 months), and three patients were in third relapse at 29, 32, and 39 months from diagnosis (Tables 1 and 2).

Surgery was performed in 14 patients before chemotherapy (primary surgery). Surgery was complete in 11 of these patients.

After the mobilizing cycle, 29 patients achieved the required $CD34^+$ cell number (median, 12.1 $\times$ 10^6/kg; range, 5.52 to 25.5) with a median of two aphereses (range, one to six). Three patients failed ($CD34^+$ 0, 1.29, and 2.41 $\times$ 10^6/kg) and received only one course of HDCT (in the first two patients bone marrow was added). Another patient received only one course because she had veno-occlusive disease after the first course and died of multiple organ failure.

As of April 1, 2001, 28 patients had undergone two courses of high-dose carboplatin and etoposide, whereas four patients had one course, for a total of 60 courses.

A median of 10 days (range, 7 to 14 days) was required to reach a granulocyte count greater than 0.5 $\times$ 10^9/L, a median of 11 days (range, 8 to 16 days) was required to reach a granulocyte count greater than 1 $\times$ 10^9/L, a median of 12 days (range, 4 to 30 days) was required to reach a platelet count greater than 25 $\times$ 10^9/L, and a median of 15 days (range, 7 to 30 days) was required to reach a platelet count greater than 50 $\times$ 10^9/L. The median time for hematologic recovery was similar (no significant difference) after the first and the second course of high-dose carboplatin and etoposide.

Severe nonhematologic toxicity, according to the Bearman score, was present in only five courses: grade 3 stomatitis was present in four courses and grade 3 hepatic toxicity was present in one course. There was no significant difference in nonhematologic toxicity between the first and the second course of chemotherapy.

As shown in Table 3, 11 of 32 patients were in CR before HDCT, whereas 21 patients underwent HDCT with evident disease. After the mobilizing cycle, 11 patients were in CR, eight were in PR, and 13 had SD. After HDCT, 15 patients were in CR, three were in PR, eight had SD, five had PD, and one patient died of toxicity. Four additional CRs were obtained with HDCT among the eight patients in PR after induction chemotherapy. None of the 13 patients in SD entered a remission after HDCT. Surgery was performed in 11 patients after HDCT (secondary surgery) and was definitive in 10 patients. Surgery was not performed in five patients because of PD and in four patients because of CR. At the end of treatment, 25 patients were in CR and six had PD.



Fig 2. Overall patient survival from the day of CE treatment. ○, Dead.

As of April 1, 2001, 14 patients (43.7%) are alive, with a median survival time of 20 months from study entry (range, 7 to 36 months): four are in first CR at a median of 21 months (range, 7 to 36 months) from study entry, three are in second CR at 8, 20, and 24 months, and one is in fourth CR at 30 months. Six patients are alive with disease at 18 months (range, 11 to 26 months). Eighteen patients (56%) died: 17 of disease at 16 months from study entry (range, 8 to 39 months) and one of toxicity at 3 months (multiple organ failure). Transplantation-related mortality was 3.1%. The relapse or PD rate was 84.4%: 21 patients (65.6%) relapsed with a median time of 8 months (range, 2 to 15 months) and six patients (18.8%) did not respond to treatment.

The 3-year overall survival rate is 20% (Fig 2) and the 3-year disease-free survival is 12% (Fig 3). The median follow-up time is 18.5 months (range, 3 to 39 months).



Fig 3. Disease-free survival. ○, Relapse; +, disease-free.

DISCUSSION

The outlook for patients with high-grade osteosarcoma in metastatic relapse remains poor. When the lung is the only site of the disease recurrence, a surgical approach in which all metastases are removed has been advocated as potentially curative, with a reported 5-year survival rate from the first thoracotomy of 23% to 50%.[13,34-41] The prognosis of these patients is correlated with the relapse-free interval from initial diagnosis, the number and the sites of the metastases, and the complete metastasectomy.[13] Incomplete surgery or development of bone metastases carries a worse prognosis, with a 0% 4-year overall survival rate.[39]

Chemotherapy in the management of metastatic osteosarcoma has no proven benefit, especially in heavily pretreated patients.[35,40-44] However, a number of regimens have been reported to have been used in these situations, and the published data are difficult to analyze.[25,45-47] There are but isolated reports of the use of HDCT in patients with metastatic osteosarcoma.[18,19,27,48,49]

In an attempt to improve the survival of patients affected by high-grade osteosarcoma in metastatic relapse, the Italian and Scandinavian Sarcoma Group devised a phase II protocol that consists of high doses of carboplatin and etoposide and PBSC reinfusion. Each of these agents has considerable activity against osteosarcoma and a suitable toxicity profile. Dose-limiting toxicity consists of stomatitis and diarrhea for high-dose etoposide and neuropathy, nephrotoxicity, and hepatic toxicity for high-dose carboplatin. Toxicity data on double high-dose treatment using carboplatin and etoposide are derived from phase I/II studies on adult germ cell tumors and from one pediatric study on mixed tumors. In one study, high-dose therapy was a part of the primary therapy.[50] In the other three, high-dose therapy was a part of salvage therapy, usually after extensive use of chemotherapy containing platinum.[27,51,52]

The patients enrolled onto this study do not have a good prognosis. Twenty-one patients were in first relapse at a median of 20 months from diagnosis. All of these patients except one had two or more mono- or bilateral metastases. Eight patients were in second relapse with bilateral metastases of the lung (five patients), lung and bone (one patient), lung and lymph nodes (one patient), and bone (one patient). Three patients were in third relapse.

The first-line therapy is shown in Table 1. The patients in second or in third relapse received surgery. Therefore, all patients were heavily pretreated, even though a single course of cyclophosphamide and etoposide allowed an adequate collection for two re-infusions. Only three patients failed to achieve the required number of $CD34^+$ cells, and they received just one course of high-dose carboplatin and etoposide. During the mobilizing cycle, no patients had PD and five patients were in PR.

After carboplatin and etoposide administration, trilineage engraftment was promptly observed in all patients, and there was no significant difference between the first and the second course of chemotherapy. Furthermore, our results showed that a two-drug conditioning regimen containing carboplatin and etoposide is well tolerated. We observed severe extra-hematopoietic toxicity in only five courses: severe stomatitis requiring morphine in four courses and severe hepatic toxicity in one course (this patient died of multiorgan failure only 3 months after study entry). After two cycles of HDCT, five patients were in PD, five were in PR, and four were in CR. At the end of treatment, with primary or secondary surgery, there were 25 patients in CR and six in PD. It is important to note that most of these patients had received cisplatin in first-line therapy and such patients may develop resistance to platinum agents. Such acquired cross-resistance after exposure to cisplatin has been reported in an osteosarcoma cell line.[53] Twenty one patients (65.6%) relapsed, with a median time of 8 months.

In conclusion, combining surgery with HDCT can render a large proportion of patients disease-free. The evidence that patients in PR after induction therapy can reach CR after HDCT indicates that this procedure may be useful for these patients. Additional maintenance treatment or completely novel strategies, such as nonmyeloablative allogeneic transplantation, need to be explored to eliminate minimal residual disease. For patients in SD after primary treatment, HDCT seems scarcely efficacious. For these chemoresistant patients, completely new strategies are warranted.

ACKNOWLEDGMENT

We thank Andrew M. Garvey, BA(Hons), Licentiate of Trinity College London(Teaching English as a Second or Foreign Language) for editorial assistance.

REFERENCES

1. Bacci G, Picci P, Ruggieri P, et al: Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities: The Istituto Rizzoli's experience in 127 patients treated preoperatively with intravenous methotrexate (high versus moderate doses) and intraarterial cisplatin. Cancer 65:2539-2553, 1990

2. Bacci G, Picci P, Ferrari S: Primary chemotherapy and delayed surgery for non metastatic osteosarcoma of the extremities: results in 164 patients pre-operatively treated with high doses of methotrexate followed by Cisplatin and Doxorubicin. Cancer 72:3227-3238, 1993

3. Meyers PA, Gorlik R, Heller G, et al: Intensification of preoperative chemotherapy for osteogenic sarcoma: Results of the Memorial Sloan-Kettering (T12) Protocol. J Clin Oncol 16:2452-2458, 1998

4. Saeter G, Alvegard TA, Elomaa I, et al: Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of pre-operative chemotherapy with single agent high-dose methotrexate: A Scandinavian Sarcoma Group study. J Clin Oncol 9:1766-1775, 1991

5. Bacci G, Picci P, Avella M, et al: Effect of intraarterial versus intravenous cisplatin in addition to systemic Adriamycin and high-dose methotrexate on histologic tumor response of osteosarcoma of the extremities. J Chemother 4:189-195, 1992

6. Lewis IJ, Weeden S, Machin D, et al: Received dose and dose-intensity of chemotherapy and outcome in nonmetastatic extremity osteosarcoma: European Osteosarcoma Intergroup. J Clin Oncol 18:4028-4037, 2000

7. Saeter G: Treatment of osteosarcoma with high-dose methotrexate-containing neoadjuvant chemotherapy: Scandinavian Sarcoma Group data. Med Pediatr Oncol 27:263, 1996 (abstr)

8. Saeter G, Wiebe T, Wiklund T, et al: Chemotherapy in osteosarcoma: The Scandinavian Sarcoma Group experience. Acta Orthopaedica Scandinavia 70:S74-S82, 1999 (suppl 285)

9. Smith MA, Ungerleider RS, Horowitz ME, et al: Influence of doxorubicin dose-intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83:1460-1470, 1991

10. Bacci G, Picci P, Avella M, et al: The importance of dose-intensity in neoadjuvant chemotherapy of osteosarcoma: A retrospective analysis of high dose methotrexate, cisplatinum and Adriamycin used preoperatively. J Chemother 2:127-135, 1990

11. Bacci G, Ferrari S, Delepine N, et al: Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin. J Clin Oncol 16:658-663, 1998

12. Picci P, Sangiorgi L, Rougraff BT, et al: Relationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcoma. J Clin Oncol 12:2699-2705, 1994

13. Saeter G, Hoie J, Stenwig AE, et al: Systemic relapse of patients with osteogenic sarcoma: Prognostic factors for long term survival. Cancer 75:1084-1093, 1995

14. Saeter G: Treatment strategies and outcome in metastatic (relapsed) osteogenic sarcoma: The Scandinavian Sarcoma Group (SSG) Experience. Med Pediatr Oncol 27:264, 1996 (abstr)

15. Bacci G, Briccoli A, Picci P, et al: Osteosarcoma of the extremities metastatic at presentation: Results obtained with primary chemotherapy followed by simultaneous resection of the primary and metastatic lesions. Cancer J 3:213-218, 1990

16. Marina NM, Pratt CB, Rao BN, et al: Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer 70:2722-2727, 1992

17. Meyers PA, Heller G, Healey JH, et al: Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol 11:449-453, 1993

18. Miniero R, Brach del Prever A, Vassallo E, et al: Feasibility of high-dose chemotherapy and autologous peripheral blood stem cell transplantation in children with high grade osteosarcoma. Bone Marrow Transplant 22:S37–S40, 1998 (suppl 5)

19. Fagioli F, Brach del Prever A, Tienghi A, et al: High dose chemotherapy in metastatic osteosarcoma. Bone Marrow Transplant 27:S329-S330, 2001 (suppl 1) (abstr)

20. Ferrari S, Sassoli V, Orlandi M, et al: Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen. J Chemother 5:135-141, 1993

21. Graf N, Winkler K, Betlemovic M, et al: Methotrexate pharmacokinetics and prognosis in osteosarcoma. J Clin Oncol 12:1443-1451, 1994

22. McHaney VA, Thibadoux G, Hayes FA, et al: Hearing loss in children receiving cisplatin chemotherapy. J Pediatr 102:314-317, 1983

23. Jaffe N, Keifer R III, Robertson R, et al: Renal toxicity with cumulative doses of *cis*-diamminedichloroplatinum-II in pediatric patients with osteosarcoma: Effect on creatinine clearance and methotrexate excretion. Cancer 59:1577-1581, 1987

24. Marina NM, Poquette CA, Cain AM, et al: Comparative renal tubular toxicity of chemotherapy regimens including ifosfamide in patients with newly diagnosed sarcomas. J Pediatr Hematol Oncol 22:112-118, 2000

25. Saeter G, Talle K, Solheim O: Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. Cancer Chemother Pharmacol 36:172-175, 1995

26. Saeter G, Alvegard TA, Monge OR, et al: Ifosfamide and continuous infusion etoposide in advanced adult soft tissue sarcoma: A Scandinavian Sarcoma Group phase II study. Eur J Cancer 33:1551-1558, 1997

27. Santana VM, Schell MJ, Williams R, et al: Escalating sequential high dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors. Bone marrow Transplant 10:457-462, 1992

28. Meyer WH, Pratt CB, Rao BN, et al: Curative therapy for osteosarcoma without cisplatin preliminary experience with SJCRH OS-91. Med Pediatr Oncol 27:226, 1996 (abstr)

29. Petrilli AS, Kechichian R, Broniscer A, et al: Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma. Med Pediatr Oncol 33:71-75, 1999

30. Robson H, Meyer S, Shalet SM, et al: Comparative evaluation of cisplatin and carboplatin sensitivity in osteosarcoma cell lines. Med Pediatr Oncol 33:167, 1999 (abstr)

31. Meyer WH, Pratt CB, Poquette CA, et al: Carboplatin/ifosfamide window therapy for osteosarcoma: Results of the St Jude Children's Research Hospital OS-91 trial. J Clin Oncol 19:171-185, 2001

32. Bearman SI, Appelbaum FR, Buckner CD, et al: Regimen related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562-1568, 1998

33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958

34. Schaller RT, Haas J, Schaller J: Improved survival in children with osteosarcoma following resection of pulmonary metastases. J Pediatr Surg 17:546-550, 1982

35. Meyer WH, Schell MJ, Kumar APM, et al: Thoracotomy for pulmonary metastatic osteosarcoma: An analysis of prognostic indicators of survival. Cancer 59:374-379, 1987

36. Belli L, Scholl S, Livartowski A, et al: Resection of pulmonary metastases in osteosarcoma: A retrospective analysis of 44 patients. Cancer 63:2546-2550, 1989

37. Snyder CL, Saltzman DA, Ferrel KL, et al: A new approach to the resection of pulmonary osteosarcoma metastases: Results of aggressive metastasectomy. Clin Orthop 270:247-253, 1991

38. Skinner KA, Eiber FR, Carmack Holmes E, et al: Surgical treatment and chemotherapy for pulmonary metastases from osteosarcoma. Arch Surg 127:1065-1071, 1992

39. Ward W, Mikaelian K, Dorey F, et al: Pulmonary metastases of stage 11B extremity osteosarcoma and subsequent pulmonary metastases. J Clin Oncol 12:1849-1858, 1994

40. Han MT, Telander RL, Pairolero PC, et al: Aggressive thoracotomy for pulmonary metastatic osteogenic sarcoma in children and young adolescents. J Pediatr Surg 16:928-933, 1981

41. Goorin AM, Delorey M, Lack EE, et al: Prognostic significance of complete surgical resection of pulmonary metastases in patients with osteogenic sarcoma: analysis of 32 patients. J Clin Oncol 2:425-431, 1984

42. Cassano W, Graham-Pole J, Dickinson N: Etoposide, cyclophosphamide, cisplatin and doxorubicin as neoadjuvant chemotherapy for osteosarcoma. Cancer 68:1899-1902, 1991

43. Pratt CB, Epelman S, Jaffe N: Bleomycin, cyclophosphamide and dactinomycin in metastatic osteosarcoma: Lack of tumor regression in previously treated patients. Cancer Treat Rep 71:421-423, 1987

44. Winkler K, Garbe T, Bieling P, et al: COSS experience in treatment results of synchronous and metachronous metastases in osteosarcoma: Osteosarcoma and adult soft tissue sarcomas—trends. Aviano 1991, p 32 (abstr)

45. Morgan E, Baum E, Bleyer WA, et al: Treatment of patients with metastatic osteogenic sarcoma: A report from the Children's Cancer Study Group. Cancer Treat Rep 68:661-664, 1984

46. Chawla SP, Rosen G, Lowenbraun S, et al: Role of high dose ifosfamide (HDI) in recurrent osteosarcoma. Proc Am Soc Clin Oncol 9:310, 1990 (abstr)

47. Michelagnoli MP, Lewis IJ, Gattamaneni HR, et al: Ifosfamide/etoposide alternating with high dose methotrexate: Evaluation of a chemotherapy regimen for poor risk osteosarcoma. Br J Cancer 79:1174-1178, 1999

48. Valteau-Couanet D, Kalifa C, Benhamou E, et al: Phase II study of high dose thiotepa (HDT) and hematopoietic stem cell transplantation (SCT) support in children with metastatic osteosarcoma. Med Pediatr Oncol 27:239, 1996 (abstr)

49. Colombat PH, Biron P, Coze C, et al: Failure of high-dose alkylating agents in osteosarcoma. Bone Marrow Transplant 14:665, 1994 (abstr)

50. Motzer RJ, Mazumdar M, Gulati SC, et al: Phase II trial of high dose carboplatin and etoposide with autologous bone marrow transplantation in first line therapy for patients with poor risk germ cell tumors. J Natl Cancer Inst 8:1828-1835, 1993

51. Lampe H, Dearnaley DP, Price A, et al: High dose carboplatin and etoposide for salvage chemotherapy of germ cells tumors. Eur J Cancer 31:717-723, 1995

52. Broun ER, Nichols CR, Mandanas R, et al: Dose escalation of high dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors. Bone Marrow Transplant 16:353-358, 1995

53. Asada N, Tsuchiya H, Ueda Y, et al: Establishment and characterization of an acquired cisplatin-resistant subline in a human osteosarcoma cell line. Anticancer Res 18:1765-1768, 1998